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ABSTRACT  
Background: The emergence of Candida albicans strains resistant to fluconazole (FLZ) had raised interest on combining other antifungals with 
FLZ. In vitro and clinical studies had indicated synergistic interaction between terbinafine and FLZ against strains resistant to FLZ and 
improved therapeutic efficacy. Objective: Formulation and evaluation of fixed dose combination (FDC) tablets of terbinafine HCl (TH) and FLZ 
for avoidance of resistance and improved therapeutic efficacy against C. albicans infections.  Method: The compatibility of TH and FLZ together 
and with excipients was determined by FTIR spectroscopy. A UV-visible spectroscopic Q-absorbance ratio method was developed and validated 
for linearity, accuracy, precision, LOD and LOQ for simultaneous estimation of TH and FLZ. The FDC tablets was prepared by wet granulation 
using hydroxy propyl cellulose (1%, 2%, 3%, 4% and 5%) as binder and evaluated for pre-compression and post-compression parameters. 
Result and Discussion: The TH and FLZ were compatible together and with excipients used in FDC. The linearity range was found to be 0.5-3.0 
µg/ml and 80-400 µg/ml for TH and FLZ, respectively. Percent RSD was less than 2% indicating good accuracy and precision for proposed  
method. The hardness and disintegration time of tablets increased and friability decreased with increased binder concentration. Formulation 
F2 and F3 showed more than 80% drug release within 30 minutes. Conclusion: The TH and FLZ were compatible and can be formulated as a 
FDC tablet. The UV-Visible spectrophotometric method developed for simultaneous estimation was simple, accurate and sensitive.  
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1. INTRODUCTION 
Candida albicans is the most important fungal strain 
accountable for most of the localized and systemic fungal 
infections1. Systemic candidiasis is the leading cause of 
mycosis-associated mortality in the United States and is 
globally recognized as a cause of significant morbidity 2. 
Immunocompromised patients, such as AIDS patients or are 
neutropenic due to cancer therapy, are at specific threat of 
evolving local C. albicans infections, which may become 
systemic 3, 4. Fluconazole (FLZ) is an orally active triazole 
agent, well established as a first-line treatment for localized 
and systemic C. albicans infections 1. In the past decades, 
advent of resistant C. albicans strains to FLZ on long term 
suppressive therapy has been reported in AIDS patient with 
oropharyngeal candidiasis 5, 6. An attractive therapeutic 
option in these circumstances is combining other antifungals 
with the FLZ for synergistic effect and widened spectrum 
against FLZ resistant fungal strains. The use of terbinafine an 
orally and topically active antifungal has been recommended 
in combination with FLZ for the cases with FLZ resistant C. 
albicans 7.  Terbinafine is act as a fungicidal against a broad 
spectrum of fungi including dermatophytes, filamentous, 
dimorphic organisms and some yeast such as Candida 
parapsilosis 8.  
Synergistic interactions of terbinafine with azoles and other 
compounds against Candida albicans have been reported by 
many investigators. Ghonnoum and Elewski 6 had reported 
the successful treatment of oropharyngeal candidiasis 
patients with a combination of FLZ and terbinafine who had 
also FLZ-refractory. In an in vitro study, Barchiesi and 
colleagues concluded a synergistic interaction between 
terbinafine and FLZ against C. albicans strain with reduced 
susceptibility to FLZ 7. The above evidences suggested that 
combining the terbinafine and FLZ in fixed dose 
combinations (FDC) can be a better approach for the 
treatment of cases associated with FLZ resistant C. albicans. 
FDC are dosage forms which contain two or more active 
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ingredients in fixed proportions in same formulations. FDC 
can offer enough advantages as compared to traditional 
monotherapy like improved patients compliance, simple 
dosage schedule, greater efficacy compared to monotherapy, 
reduced adverse events and synergistic effect 9. 
So, in the present research work, fixed dose combination 
(FDC) tablets of terbinafine hydrochloride (TH) and FLZ has 
been formulated by wet granulation using hydroxy propyl 
cellulose (HPC) as a binder and starch as disintegrating 
agent. During the preformulation studies the compatibility of 
the TH and FLZ together and with different excipients were 
evaluated.  A UV spectrophotometric method i.e Q-anlysis or 
Q-absorbance ratio for the simultaneous analysis of TH and 
FLZ was developed and validated. The ratio of absorbance at 
two wavelengths is constant for two different 
concentrations. In this method, the absorption of the two 
components is measured at two different wavelengths. One 
being the absorption at  max of one of the component and 
other is absorption at iso-absorptive point 10.  
2. MATERIALS AND METHODS 
Fluconazole and terbinafine HCl was procured from Lark 
Pharmaceuticals, Bhiwandi, India as gift sample. HPC, starch, 
magnesium stearate, talc and lactose were procured from 
CDH Chemicals, Mumbai.  
2.1 Preformulation studies  
Preformulation studies are carried out in order to determine 
the physiochemical properties of drug which helps in the 
design of a safe, efficacious and stable dosage form. The 
drugs (TH and FLZ) were physically characterized on the 
basis of color and odor. All the physical characterization 
were observed and compared with the monograph in official 
Pharmacopoeia. Melting point of TH and FLZ was 
determined by using digital melting point test apparatus. 
2.1.1 Absorption maxima (max) and preparation of 
calibration curve 
The max of TH was determined in 0.1N HCl by scanning the 
3.0 µg/ml solution in range of 400-200 nm using UV-Visible 
spectrophotometer (Lab India, Mumbai). The calibration 
curve of TH was prepared by dissolving 100 mg in small 
volume of 0.1N HCl and final volume was adjusted up to 
100ml with the same solvent. A series of standard solution of 
concentrations 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 µg/ml were 
prepared and absorbance was measured at 222 nm against 
blank using an UV-Visible spectrophotometer. 
The max of FLZ was determined in 0.1N HCl by scanning the 
400 µg/ml solution in range of 400-200 nm using UV-Visible 
spectrophotometer. An accurately weighed 100 mg of FLZ 
was dissolved in small volume of 0.1N HCl in the 100 ml 
volumetric flask and final volume was adjusted with the 
same solvent. A series of standard solutions of 
concentrations 80, 120, 160, 200, 240, 280, 320, 360 and 
400 µg/ml of FLZ were prepared.   The measurements of 
absorbance were done at 260 nm against blank using an UV-
Visible spectrophotometer. 
2.1.2. Fourier transformed infrared (FTIR) studies of 
pure drugs 
FTIR spectra of pure drug were observed and analyse by 
potassium bromide (KBr) press pellet method.  Pure drug 
TH was uniformly mixed with dry powdered KBr in the ratio 
of 1:100 and mixture was then compressed into transparent 
disc under high pressure using special dies. The disc was 
placed in FTIR spectrophotometer (Shimadzu IR Affinity-1) 
and spectrum was recorded. Same procedure was followed 
for FLZ and spectrum was recorded.  
2.1.3 Compatibility study of Drug-drug and drug-
excipient by FTIR spectroscopy 
TH and FLZ compatibility, together and with the excipients 
used in the formulation of tablets was determined by FTIR 
spectrophotometer. TH and FLZ physical mixture (250 
mg:150 mg) was prepared by triturating them together in a 
clean and dried mortar-pestle. The one part of above 
prepared physical mixture and hundred part of FTIR grade 
KBr was mixed together properly. Then using KBr press 
pellet a thin and transparent pellet was prepared. The FTIR 
spectrum, of pure TH and FLZ, recorded by KBr disc method 
was compared for specific peak positions of different 
functional groups.  
To determine the compatibility of TH and FLZ with 
excipients used for formulation of FDC tablets, triturate the 
TH, FLZ, HPC, starch, talc, magnesium stearate and lactose 
with ethanol. The prepared physical mixture was dried in a 
hot air oven to completely remove the ethanol and any 
traces of moisture at 60°C and passed through the BSS 
number 85. The FTIR spectrum of the physical mixture was 
recorded by KBr disc method and peak positions of 
important functional groups in pure drugs were compared.  
2.2 Development and validation of simultaneous 
estimation method for TH and FLZ by UV-Visible 
spectrophotometer 
Q-Absorbance ratio or Q-Analysis method for simultaneous 
estimation of TH and FLZ by UV-Visible spectrophotometer 
was developed and validated 10-12.  
2.2.1 Standard stock solutions of TH and FLZ 
100 mg of TH was dissolved in small volume of 0.1N HCl in 
100 ml volumetric flask. The solution was sonicated for 10 
minutes and adjusted the final volume with 0.1N HCl. From 
standard stock solution (1000 µg/ml), by pipetting out 1ml 
in a 100 ml volumetric flask working stock solution    (10 
µg/ml) was prepared and final volume was adjusted with 
0.1N HCl. Then in series of 10 ml volumetric flasks pipetting 
out 0.5, 1.0, 1.5, 2.0, 2.5 and 3 ml from working stock 
solution and volume was made up to the mark with the same 
solvent. For FLZ standard solution 100 mg of drug was 
dissolved in small volume of 0.1N HCl in a100 ml volumetric 
flask. The solution was sonicated for 10 minutes and final 
volume adjusted. From above solution 0.8, 1.2, 1.6, 2.0, 2.4, 
2.8, 3.2, 3.6 and 4.0 ml were pipetted out in series of 10 ml 
volumetric flask and final volume was made up with 0.1N 
HCl.   
2.2.2 Selection of wavelength of maximum absorbance 
(max) 
For 3µg/ml solution of TH pipetting out 3 ml from working 
stock solution of drug in 10 ml volumetric flask and final 
volume was adjusted with 0.1N HCl. For 400µg/ml FLZ 
solution was prepared by pipetting out 4 ml from standard 
stock solution in 10 ml volumetric flask and final volume 
was adjusted up with 0.1N HCl. Both the solutions were 
scanned in the range of 400-200 nm against blank solution 
(0.1N HCl) using UV-Visible spectrophotometer.  
2.2.3 Determination of iso-absorptive point 
Iso-absorptive point was determined by preparing 1.5 µg/ml 
solutions of TH and 200 µg/ml of FLZ and by scanning in the 
range of 400-200 nm against 0.1N HCl as blank using an UV-
Visible spectrophotometer. An overlain spectrum of TH and 
FLZ was found and iso-absorptive point was determined. 
2.2.4 Determination of Linearity range 
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Linearity range of TH was determined by preparing different 
concentrations i.e. 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 µg/ml from 
working standard solution and at 222 nm and 239 nm 
absorbance was taken against 0.1N HCl as a blank. Linearity 
curve was plotted between concentration vs. absorbance. 
Linearity of FLZ was determined by preparing different 
concentrations 160, 200, 240, 300, 360 and 400 µg/ml were 
prepared from standard stock solution and absorbance was 
measured at 222 nm and 239 nm against 0.1N HCl as a 
blank. Than linearity curve was plotted between 
concentration vs. absorbance. 
2.2.5 Determination of Accuracy   
To determine the accuracy of the proposed method 2.0, 2.5 
and 3.0 µg/ml; and 240, 300 and 360 µg/ml solutions were 
prepared for TH and FLZ, respectively. These were the three 
different levels 80%, 100% and 120% by considering 
2.5µg/ml and 300µg/ml as 100% for TH and FLZ, 
respectively. The recovery study was performed three times 
at each level. 
2.2.6 Determination of Precision  
2.2.6.1 Intermediate Precision (Inter-day and Intra-day 
precision) 
The solutions of same concentrations were prepared as in 
the determination of accuracy. Inter-day precision both the 
drugs were analyzed individually daily once for three days at 
specified wavelengths as above. Intra-day precision was 
determined by analyzing TH and FLZ individually for three 
times in the same day at the wavelength 222 nm and 239 
nm. The standard deviation and relative standard deviation 
were calculated.         
2.2.6.2 Repeatability  
In repeatability, 3.0 µg/ml and 300 µg/ml solutions were 
prepared for TH and FLZ, respectively. The measurement of 
absorbance was taken at 222 nm and 239 nm against 0.1N 
HCl as a blank. The experiment was done six times. The 
standard deviation and relative standard deviation was 
calculated. 
2.2.6.3 Reproducibility 
The absorbance was measured by two analysts and values 
obtained were evaluated using t-test to verify their 
reproducibility. 2.0 µg/ml and 300 µg/ml solutions were 
prepared from stock solutions separately of TH and FLZ, 
respectively and analyzed by one analyst (analyst 1) at 222 
nm and 239 nm. Same solutions were prepared by another 
analyst (analyst 2) and values obtained were evaluated 
using t-test to verify their reproducibility. 
2.2.7 Limit of Detection (LOD)    
The LOD is defined as in a sample lowest concentration of a 
drug that can be detected, but not necessarily quantified, 
under the given conditions of the test. LOD was calculated 
from the obtained data from the linearity studies. The slope 
of the linearity plot was determined and calculated by 
formula given below. 
LOD = 3.3(S/b)                                                                                                                                           
                           Where,  
                                        S = Standard deviation of the residuals 
around the regression line. 
                                        b = Slope of the regression line. 
2.2.8 Limit of Quantitation (LOQ)  
The LOQ is defined as the lowest concentration of a drug in a 
sample that can be determined with acceptable accuracy and 
precision under the given conditions of test. Limit of 
quantitation can be calculated from standard deviation of 
the response and slope using formula given below.  
LOQ = 10(S/b)                                                                                                                        
                              Where, 
                                         S = Standard deviation of the residuals 
around the regression line. 
                                         b= Slope of the regression line. 
2.3 Formulation and Evaluation of FDC tablets 
2.3.1 Formulation of granules 
For the formulation of FDCs tablets wet granulation method 
was used and to prepare granules, HPC and starch were used 
as binder and disintegrant respectively. Talc, magnesium 
stearate and lactose were used as glidant, lubricant and 
diluents, respectively (Table No. 1). Firstly TH, FLZ, HPC, 
starch and lactose were passed through British Standard 
Sieve (BSS) 60.  Then TH, FLZ, HPC, lactose and half of the 
starch were mixed uniformly and sufficient quantity of 
distilled water was added with continuous mixing to obtain 
wet dough mass.  The wet mass was shifted through BSS 10 
and dried in hot air oven at 60ºC till moisture content was 
achieved in the range of 1.5-2%. The dried mass was then 
passed through the BSS 16/44. The granules which were 
retained on the BSS 44 were considered coarse granules and 
the granules which passed through BSS 44 are considered as 
fines. To the granules, remaining starch, talc and magnesium 
stearate previously passed through BSS 80 were mixed 
uniformly.
 
Table No. 1 Formulation formula for granules using HPC as binder 
Sr. 
No. 
Ingredient 
(mg) 
Formulation Codes 
F1 F2 F3 F4 F5 
1 Terbinafine Hydrochloride 250 250 250 250 250 
2 Fluconazole  150 150 150 150 150 
3 Hydroxy propyl cellulose 10 15 20 25 30 
4 Starch (10%w/w) 50 50 50 50 50 
5 Talc (1%w/w) 5 5 5 5 5 
6 Magnesium Stearate (1%w/w) 5 5 5 5 5 
7 Lactose 35 30 25 20 15 
              Weight of tablet 500 mg 500 mg 500 mg 500 mg 500 mg 
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2.3.2 Evaluation of granules 
2.3.2.1 Mean granule size 
Mean granule size was determined using electric sieve 
shaker (Eectrolab, Mumbai, India) in which different BSS 
were arranged in ascending order of sieve number (16, 22, 
44 and 60). Accurately weighed 30 g of granules was placed 
on the top sieve and sieve shaker was operated for 20 min. 
The granules retained on each sieve were weighed and 
granules retained on each sieve were determined. The mean 
granule size was calculated by finding out the average size of 
the sieve opening, through which the granules were passed 
and the size of the sieve opening, on which the granules were 
retained. The weight retained (X) on each sieve was 
multiplied with average sieve opening (Y) of two successive 
sieves. The mean granule size was determined using formula 
given below 13. 
Mean granule size (µm) = ΣXY/Weight of granules                                                          
2.3.2.2 Bulk and tapped density  
 Bulk density was measured by taking 35ml granules in 50 
ml measuring cylinder. The granules volume at initial stage 
was recorded in the form of bulk volume. The placement of 
measuring cylinder was done on tapped density tester (EDT-
1020, Electro lab, India). The falling rate of drops was 
250/minutes from the height of 3 mm ± 10%. The volume of 
powder bed was recorded after every increase of 250 drops 
up to constant volume change. The final recorded volume 
was known as tapped volume. The BD and TD were 
measured as ratio of weight of the powder by bulk volume 
and tapped volume14. 
2.3.2.3 Determination of Hausner ratio 
Hausner ratio is an indirect index of ease of powder flow. 
Hausner ratio was calculated formula given below. 
Hausner ratio = TD/BD                                                                                                          
2.3.2.4 Determination of Carr’s consolidation index 
Carr’s consolidation index was calculated by formula given 
below. 
Carr’s consolidation index (%) = [(TD-BD)/TD] x 100 
2.3.2.5 Determination of angle of repose 
Angle of repose acts as important parameter to determined 
the flow property of granule. Funnel was placed and fixed at 
above of graph paper, which was placed on horizontal flat 
surface. The granule was carefully poured through the funnel 
until the apex of the conical pile just touched tip of the 
funnel. The radius (r) of base of pile and height (h) of the pile 
was determined. The angle of repose (θ) was calculated by 
using formula given below. 
θ = tan-1 h/r 
2.3.2.6 Percentage of fines 
For the determination of percentage fines, a known weight of 
dried granules was passed through BSS 44. The weight of 
granules which passed through sieve number 44 was 
recorded and percentage fine was calculated with respect to 
total weight of granules.  
2.3.2.7 Moisture content 
Moisture content (%) of granules was determined using a 
digital moisture balance (MA45, Sartorius, Mumbai, India). 
 
 
2.3.3 Compression of FDC tablets 
The granules were compressed into 500 mg tablets on a 10 
station rotary tablet compression machine (Rimek, 
Ahmadabad, India) using 13 mm die cavity. 
2.3.4 Evaluation of FDC tablets 
2.3.4.1 General Appearance 
The compressed tablets were observed for color, shape, 
surface irregularities, cracks or any other defects. 
2.3.4.2 Average weight 
Twenty tablets were weighed individually and the average 
weight was calculated. The individual tablet weights were 
then compared to the average weight and percent deviation 
was calculated.  
2.3.4.3 Thickness and Hardness  
The thicknesses of randomly selected 10 tablets were 
determined using digital vernier caliper (Mitutoya, Japan). 
Hardness of tablets (n=10) for each batch was determined 
using Monsanto hardness tester (Cadmach, Ahmedabad, 
India). 
2.3.4.4 Determination of Friability 
Friability was determined using Roche friabilator 
(Electrolab). Initial weight of the 10 tablets was recorded 
(W1). The tablets were placed in the friabilator and rotated 
at 25 rpm for four minutes. After that, tablets were taken out 
and final weight was determined (W2). The percentage 
friability was determined by using formula given below. 
Friability (%) = [(W1-W2)/W1] x 100 
2.3.4.5 Disintegration time 
The disintegration time for tablets (n=6) for F2, F3, F4 and 
F5 was determined using disintegration test apparatus (ED-
2SAPO, Electrolab, India) at 37 ± 0.5°C in 0.1N HCl. 
2.3.4.6 Drug content 
Drug content of formulation F2 and F3 was determined. 
Average weight of 10 tablets was determined and then 
tablets were crushed to form powder. Powder having weight 
equivalent to average weight was taken in 100 ml of 
volumetric flask and dissolved in small volume of 0.1N HCl. 
Final volume was adjusted with 0.1N HCl. Then the flask was 
shaken for 24 h using a water bath shaker and solution was 
filtered. After suitable dilution of filtrate, absorbance was 
measured at 222 nm and 239 nm for TH and FLZ, 
respectively using an UV-Visible spectrophotometer and 
drug content was calculated by Q-Analysis method.  
2.3.4.6 In vitro drug release 
In vitro drug release study of the tablets (F2 and F3) was 
performed using USP Type II dissolution test apparatus 
(LABINDIA DS 8000, India) using 900 ml 0.1N HCl as a 
dissolution medium maintained at 37 ± 0.5°C. The paddles 
were rotated at speed of 75 rpm. At regular intervals of time 
for 1 hour, 10 ml sample was withdrawn and replaced with 
equal volume of 0.1N HCl to maintain the sink condition. 
Samples were filtered through whatmann filter (0.42 µm) 
paper and after appropriate dilutions absorbance was 
recorded at 222 nm and 239 nm for TH and FLZ, respectively 
using an UV-Visible spectrophotometer. The T80% (Time to 
release 80% of drug) was calculated from percent 
cumulative drug release vs. time plots. 
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3. RESULTS 
3.1 Preformualtion Studies 
TH was white, odourless and sticky powder while FLZ was 
almost white and odourless powder. The melting point of TH 
and FLZ was found to be 205.66 ± 1.15°C and 139.66 ± 
0.57°C, respectively. The absorption maxima of TH and FLZ 
were found at 222 nm and 260 nm, respectively. The 
calibration curve of TH and FLZ in 0.1N HCl is shown in Fig. 
1a and 1b, respectively. 
 
 
Fig. 1 Calibration curve (a) TH at 222 nm in 0.1N HCl (b) FLZ at 260 nm in 0.1N HCl 
 
The FTIR spectrum of TH (Fig. 2a) showed important peaks 
at 2869.54 cm-1 (-OH stretching), 2446.81 cm-1 (-SH 
stretching), 2224.98 cm-1 (-CN stretching), 1633.78 cm-1 (-
C=O stretching), 1469.82 cm-1 (-C-H bending), 1072.47 cm-1 
(-S=O stretching) and 777.35 cm-1 (-C-Cl stretching). The 
FTIR spectrum of FLZ (Fig. 2b) showed important peaks at 
3120.96 cm-1 (OH stretching), 1211.35 cm-1 (C-F stretching), 
1621.24 cm-1 (-C=N stretching) and 2961.82 cm-1 (-C-H 
stretching).  The FTIR spectrum of drugs in combination 
(Fig. 2c) showed important peaks for TH at 2964.72 cm-1 (-
OH stretching), 2446.81 cm-1 (-SH stretching), 2227.88 cm-1 
(-CN stretching), 1621.24 cm-1 (-C=O stretching), 1465.96 
cm-1 (-C-H bending), 1076.33 cm-1 (-S=O stretching) and 
773.21 cm-1 (-C-Cl stretching). The important peaks for FLZ 
were observed at 3119.99 cm-1 (OH stretching), 1210.38 cm-
1 (C-F stretching), 1621.24 cm-1 (-C=N stretching) and 
2964.72 cm-1 (-C-H stretching). The FTIR spectrum of 
physical mixture of drugs with excipients used in 
formulation of FDC tablets (Fig. 2d) showed important peaks 
for TH at 2970.50 cm-1 (-OH stretching), 2447.77 cm-1 (-SH 
stretching), 2225.95 cm-1 (-CN stretching), 1622.20 cm-1 (-
C=O stretching), 1466.93 cm-1 (-C-H bending), 1078.07 cm-1 
(-S=O stretching) and 776.38 cm-1 (-C-Cl stretching). The 
important peaks for FLZ were observed at 3119.99 cm-1 (OH 
stretching), 1208.46 cm-1 (C-F stretching), 1622.20 cm-1 (-
C=N stretching) and 2970.50 cm-1 (-C-H stretching) 15 
. 
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Fig 2.  FTIR spectra (a) TH (b) FLZ (c) TH and FLZ physical mixture (d) Physical mixture of TH and FLZ with excipients in FDC 
tablets 
3.2 Development and validation of simultaneous 
estimation method for TH and FLZ by UV-Visible 
spectrophotometer 
The λmax of 3µg/ml solution of TH in 0.1N HCl was found to 
be 222 nm. The λmax of 400 µg/ml solution of FLZ in 0.1N HCl 
was found to be 260 nm. In the overlay spectra (Fig. 3) three 
iso-absorptive points viz. 224 nm, 239 nm and 275 nm were 
reported and the iso-absorptive point 239 nm was selected 
for further analysis.  
Linearity of TH was found in concentration range of 0.5-3.0 
µg/ml at 222 nm and 239 nm (Table 2, Fig. 4a and 4b). 
Linearity of FLZ was found in the concentration range 160-
400 µg/ml at 222 nm and 239 nm (Table No. 2, Fig. 4c and 
4d). The result of percent recovery study of proposed 
method is shown in Table 3. The percent recovery of TH at 
222 nm and 239 nm was found in the range of 100.17 ± 
0.0032% to 101.96 ± 0.0026% and 98.50 ± 0.0010% to 
101.31 ± 0.0006%, respectively. The percent recovery of FLZ 
at 222 nm and 239 nm was found in the range of 98.27 ± 
0.3125% to 102.36 ± 0.0210% and 100.57 ± 0.4318% to 
102.13 ± 0.9174%, respectively. 
 
 
Fig. 3 Overlay spectrum of TH and FLZ in 0.1N HCl 
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Table No. 2 Linearity data of TH and FLZ at 222 nm and 239 nm in 0.1 N HCl 
S.no TH FLZ 
Concentration 
(µg/ml) 
Absorbance at 
222 nm 
Absorbance at 
239 nm 
Concentration 
(µg/ml) 
Absorbance at 
222 nm 
Absorbance at 
239 nm 
1 0.5 0.178 ± 0.0020 0.035 ± 0.0010 160 0.265 ± 0.0005 0.065 ± 0.0012 
2 1.0 0.345 ± 0.0010 0.077 ± 0.0015 200 0.334 ± 0.0012 0.082 ± 0.0012 
3 1.5 0.498 ± 0.0010 0.102 ± 0.0006 240 0.431 ± 0.0010 0.105 ± 0.0010 
4 2.0 0.661 ± 0.0020 0.140 ± 0.0012 300 0.524 ± 0.0005 0.126 ± 0.0005 
5 2.5 0.802 ± 0.0010 0.178 ± 0.0010 360 0.628 ± 0.0015 0.154 ± 0.0011 
6 3.0 0.972 ± 0.0010 0.217 ± 0.0012 400 0.717 ± 0.0012 0.176 ± 0.0015 
   Mean ± SD; n=3 
 
 
Fig. 4 Calibration curve (a) TH at 222 nm (b) TH at 239 nm (c) FLZ at 222 nm (d) FLZ at 239 nm 
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Table No. 3 Percent recovery of TH and FLZ at 222 nm and 239 nm in 0.1 N HCl 
TH FLZ 
Conc* 
(µg/ml) 
222 nm 239 nm Conc 
(µg/ml) 
222 nm 239 nm 
Conc 
found 
(µg/ml) 
% R# Conc 
found 
(µg/ml) 
% R Conc found 
(µg/ml) 
% R Conc found 
(µg/ml) 
% R 
2.0 2.03 ± 
0.0057 
101.40 ± 
0.0360 
1.97 ± 
0.0026 
98.50 ±  
0.0010 
240 245.66 ±  
0.5946 
102.36 ±  
0.0210 
242.86 ±  
1.1335 
101.19 ±  
0.0316 
2.5 2.5 ± 
0.0011 
100.17 ±  
0.0032 
2.51 ± 
0.0069 
100.31 ±  
0.0006 
300 302.55 ±  
0.6755 
100.85 ±  
0.0315 
301.71 ±  
0.5861 
100.57 ±  
0.4318 
3.0 3.06 ± 
0.0208 
101.96 ±  
0.0026 
2.99 ± 
0.0549 
99.90 ±  
0.0017 
360 353.77 ±  
0.4229 
98.27 ±  
0.3125 
367.66 ±  
1.113 
102.13 ±  
0.9174 
Mean ± SD; n=3, Conc*= Concentration, %R# = Percent recovery 
 
The result of intermediate precision study is shown in Table 
No. 4. In determination of precision by repeatability study, 
percent relative standard deviation (%RSD) of TH at 222 nm 
and 239 nm was found to be 0.016 and 0.0193, respectively. 
Similarly, % RSD of FLZ at 222 nm and 239 nm was found to 
be 0.481 and 0.0171, respectively. The results of 
reproducibility study are shown in Table No. 5. 
 
Table No. 4 Intermediate precision of TH and FLZ at 222 nm and 239 nm in 0.1 N HCl 
Drug Concentration 
(µg/ml) 
Absorbance at 222 nm Absorbance at 239 nm 
Inter-day % RSD Intra-day % RSD Inter-day % RSD Intra-day % RSD 
 
TH 
2.0 0.641 ± 
0.0031 
0.483 0.646 ± 
0.0017 
0.216 0.146 ± 
0.0012 
0.822 0.144 ± 
0.0010 
0.694 
2.5 0.790 ± 
0.0015 
0.189 0.790 ± 
0.0045 
0.569 0.181 ± 
0.0012 
0.662 0.182 ± 
0.0035 
0.019 
3.0 0.917 ± 
0.0031 
0.338 0.911 ± 
0.0064 
0.702 0.216 ± 
0.0006 
0.277 0.217 ± 
0.0010 
0.555 
 
FLZ 
240 0.450 ± 
0.0023 
0.511 0.454 ± 
0.0021 
0.465 0.104 ± 
0.0006 
0.576 0.108 ± 
0.0006 
0.555 
300 0.562 ± 
0.0015 
0.267 0.556 ± 
0.0010 
0.180 0.129 ± 
0.00058 
0.387 0.127 ± 
0.0012 
0.945 
360 0.658 ± 
0.0023 
0.349 0.656 ± 
0.0015 
0.229 0.154 ± 
0.0012 
0.779 0.152 ± 
0.0010 
0.658 
  Mean ± SD; n=3 
Table No. 5 Reproducibility of TH and FLZ at 222 nm and 239 nm in 0.1 N HCl 
Drug Concentration 
(µg/ml) 
Absorbance at 222 nm Absorbance at 239 nm 
Analyst 
1 
Analyst 
2 
Calc. ‘t’ 
value 
Inference Analyst 
1 
Analyst 
2 
Calc. ‘t’ 
value 
Inference 
TH 2.0 0.643 ± 
0.0015 
0.646 ± 
0.0030 
0.8857 No 
significant 
difference 
0.145± 
0.038 
0.149 ± 
0.0035 
0.4000 No 
significant 
difference 
FLZ 300 0.566 ± 
0.0020 
0.565 ± 
0.0040 
0.8000 No 
significant 
difference 
0.126± 
0.0025 
0.128 ± 
0.0026 
0.5066 No 
significant 
difference 
  Mean ± SD; n=3, *Calc.= Calculated 
The LOD of TH at 222 nm and 239 nm was found to be 0.067 
and 0.175 µg/ml, respectively. The LOD of FLZ at 222 nm 
and 239 nm was found to be 31.09 and 94.38 µg/ml, 
respectively. The LOQ of TH at 222 nm and 239 nm was 
found to be 0.203 and 0.531 µg/ml, respectively. The LOD of 
FLZ at 222 nm and 239 nm was found to be 94.21 and 
286.00 µg/ml, respectively. 
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3.3 Formulation and evaluation of FDC tablets 
The results of evaluation of pre-compression parameters viz. 
mean granule size, tapped density, bulk density, Hausner’s 
ratio, Carr’s consolidation index, angle of repose, percent 
fines and percent moisture content of granules is shown in 
Table No. 6. The results of post-compression parameters viz. 
appearance, average weight, thickness, hardness, percent 
friability, disintegration time and drug content is shown in 
Table No. 7. The result of in vitro drug release study of the 
formulations is shown in Table No. 8 and Fig. 5. The T80% of 
TH and FLZ in F2 was found to be 11 and 10.5 minutes, 
respectively. The T80% of TH and FLZ in F3 was found to be 
12 and 11.5 minutes, respectively. 
 
Table No. 6 Pre-compression parameter of granules formulated using HPC as binder 
Formu- 
lation           
code 
Average 
granule 
size 
(µm) 
Loose bulk 
density 
(g/ml) 
Tapped  bulk 
density 
(g/ml) 
Hausner’s 
ratio 
 
Carr’s 
consolidation 
index (%) 
Angle of 
repose (º) 
Fines 
(%) 
 
Moisture 
content 
(%) 
F1 312.256 ± 
0.600 
0.574 ± 
0.005 
0.634 ± 
0.008 
1.233 ± 
0.002 
18.883 ± 
0.142 
26.61 ± 
0.824 
10.611 ± 
0.067 
1.584 ± 
0.031 
F2 320.447 ± 
0.511 
0. 478 ± 
0.004 
0.588 ± 
0.012 
1.212 ± 
0.004 
17.523 ± 
0.283 
25.68 ± 
0.813 
9.381 ± 
0.160 
1.815 ± 
0.035 
F3 340.676 ± 
0.956 
0.468 ± 
0.007 
0.566 ± 
0.011 
1.208 ± 
0.003 
17.200 ± 
0.235 
23.79 ± 
0.376 
6.245 ± 
0.068 
1.642 ± 
0.059 
F4 366.133 ± 
0.653 
0.437 ± 
0.003 
0.520 ± 
0.005 
1.189 ± 
0.004 
15.960 ± 
0.173 
21.81 ± 
0.306 
5.137 ± 
0.069 
1.593 ± 
0.049 
F5 397.693 ± 
1.223 
0.407 ± 
0.035 
0.476 ± 
0.008 
1.169 ± 
0.010 
14.427 ± 
0.837 
20.28 ± 
0.220 
2.181 ± 
0.035 
1.948 ± 
0.005 
Mean ± SD; n=3 
Table No. 7 Post compression parameters of FDC tablets formulated using HPC as binder 
Formulation 
Code 
Average 
weight (g)* 
Thickness 
(mm)** 
Hardness 
(kg/cm2)** 
Friability 
(%)# 
Disintegration 
time (min)## 
Drug content (%)# 
TH  FLZ 
F1 496.12 
± 0.0084 
4.03 
± 0.020 
4.67 
± 0.777 
1.145 
± 0.039 
- - - 
F2 502.34 
± 0.0067 
4.03 
± 0.011 
6.72 
± 0.006 
0.786 
± 0.069 
07.21 
± 0.333 
100.01 
± 0.318 
102.94 
± 0.329 
F3 503.01 
± 0.0070 
4.02 
± 0.012 
7.01 
± 0.012 
0.674 
± 0.006 
10.45 
± 0.436 
97.61 
± 0.300 
100.48 
± 0.323 
F4 502.24 
± 0.0067 
4.01 
± 0.009 
8.23 
± 0.306 
0.645 
± 0.051 
18.38 
± 0.141 
- - 
F5 504.21 
± 0.0057 
3.99 
± 0.012 
8.91 
± 0.200 
0.556 
± 0.034 
21.32 
± 0.156 
- - 
Mean ± SD, * n=20, **n=10, # n=3, ##n=6 
 
Table No. 8 In vitro drug release of FDC tablets formulated using HPC as binder 
Time (min) Cumulative drug release (%) 
F2 F3 
0 0 0 
10 77.32 ± 2.597 75.30 ± 2.352 
20 88.66 ± 3.001 86.41 ± 1.464 
30 97.62 ± 2.421 91.32 ± 3.241 
40 99.93 ± 1.276 99.62 ± 2.353 
50 - - 
60 - - 
Mean ± SD, n=3 
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Fig. 5 Cumulative percent release of TH and FLZ from FDC tablets 
 
4. DISCUSSION 
4.1 Preformulation studies 
The results of melting point determination of TH and FLZ 
indicated the purity of drug samples. The melting range of 
TH and FLZ reported in literature is 204-207°C and 138-
140°C, respectively.  
There was no major shift in the observed and standard peak 
positions of different functional groups in pure drug 
samples, indicating the purity of drug samples. Further, 
there was also no major change in the peak positions of 
different functional groups in FTIR spectrum of TH-FLZ 
physical mixture and TH-FLZ physical mixture with 
excipients as compared to the FTIR spectrum of pure drugs. 
Hence, The TH and FLZ together, and with the excipients 
used in tablet formulation were compatible.  
4.2 Development and validation of simultaneous 
estimation method for TH and FLZ by UV-Visible 
spectrophotometer 
The correlation coefficients of representative linear 
equations of TH and FLZ indicated very good linearity at 222 
nm and 239 nm. Good accuracy of the developed method 
was pointed out by the good percent recovery. The %RSD 
values (< 2) in determination of intermediate precision and 
repeatability indicated good precision of proposed method 
[9]. There was no significant difference in the determination 
performed by two different analysts indicating good 
reproducibility of proposed method. The LOD and LOQ 
values of TH and FLZ on different wavelengths indicated 
good sensitivity of proposed method [9]. 
 
 
4.3 Evaluation of granules 
The mean granule size increased with increased binder 
concentration. This might be because of better cohesion of 
solid mass due to improved wetting at higher binder 
concentration. The granules loose bulk density and tapped 
bulk density decreased with increased concentration of 
binder. This might be attributed to the increase average 
granule size with increased binder concentration.  
Hausner’s ratio is parameter that may be correlated to the 
flow property of granules. A value of angle of repose ≤ 1.25 
indicates good flow and a value > 1.25 indicates poor flow. 
The Hausner’s ratio decreased with increased binder 
concentrations. This might be because of increased mean 
granule size. All the formulations showed good flow 
property. Carr’s consolidation index is related to the flow 
rate, cohesiveness and particle size of granules. Values 
below 15% represent good flow, 15 to 25% is fair/passable 
and values above 25% are indicative of poor flow. The F5 
showed good whereas all the others formulation showed 
fair/passable flow property. Angle of repose also gives an 
idea of flow properties of granules. The angle of repose 
decreased with increased binder concentration, which 
indicated an improvement in flow. The increased granule 
size with increased binder concentrations might be the 
reason for this change. All the formulations were good flow 
properties 16.  
The percentage fines decreased with increased binder 
concentration which might be due to the better cohesion of 
solid mass at higher binder concentrations. The 1-2% of 
moisture content is necessary for compression of granules 
into tablets. If moisture content of granules is below 1% the 
tablets tends to break or laminate after compression 17. 
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4.4 Evaluation of FDC tablets 
The tablets were smooth, white, odorless and free from 
cracks or other surface irregularities. Average weight of 
tablets was found in between the range of 496.12 ± 0.0084 
mg to 504.21 ± 0.0057 mg and thickness of tablets was 
found between the ranges of 3.99 ± 0.200 mm to 4.033 ± 
0.200 mm, respectively (Table 7).  
The hardness and percent friability of the tablets increased 
and decreased, respectively with increased binder 
concentration. The percent friability of F1 was more than 
1%. Since, F1 failed in percent friability test, it was not 
considered for further evaluation. The disintegration time of 
the formulations increased with increased binder 
concentration. The disintegration time of formulation F2 and 
F3 was below 15 minutes and were considered for in vitro 
drug release study.  
The drug content of F2 and F3 was found to be satisfactory. 
The rate of drug release decreased with increased binder 
concentration. The Indian pharmacopoeia states that 
uncoated conventional tablets should release 80% of drug 
within 30 min. Formulations F2 and F3 complies with the 
Indian Pharmacopoeia standard.  
5. CONCLUSION 
The developed FDC tablets can be a better alternative for 
treatment of C. albicans resistant to fluconazole. The TH and 
FLZ were compatible to each other and with the excipients 
used in the formulation of FDC tablet. The UV-visible 
spectrophotometric method developed for the simultaneous 
estimation of TH and FLZ was simple, accurate and sensitive. 
Further, the development of FDC tablets with other suitable 
pharmaceutical excipients and determination of synergistic 
effect in vitro or in vivo could be a future prospect for the 
developed FDC tablets. 
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